We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
-11.26%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$800M
AUM Growth
-$414M
Cap. Flow
-$240M
Cap. Flow %
-29.97%
Top 10 Hldgs %
59.99%
Holding
111
New
25
Increased
21
Reduced
27
Closed
33

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$26.8M
2
MRK icon
Merck
MRK
+$25.8M
3
PFE icon
Pfizer
PFE
+$19.8M
4
ABBV icon
AbbVie
ABBV
+$14.1M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$13.5M

Top Sells

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$21.3M
2
VRNT
Verint Systems
VRNT
+$16.1M
3
JNJ icon
Johnson & Johnson
JNJ
+$12.8M
4
VTRS icon
Viatris
VTRS
+$11.3M
5
PTCT icon
PTC Therapeutics
PTCT
+$10.3M

Sector Composition

Rank Sector Weight
1 Healthcare 65.88%
2 Technology 4.53%
3 Consumer Discretionary 1.29%
4 Communication Services 0.33%
5 Financials 0.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IWM icon
1
PUT
iShares Russell 2000 ETF
IWM
$79.8B
$103M 12.88%
+900,000
New +$134M
MRK icon
2
Merck
MRK
$322B
$66.8M 8.36%
910,207
+328,567
+56% +$25.8M
SPY icon
3
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$790B
$54.1M 6.77%
+209,900
New +$64M
JNJ icon
4
Johnson & Johnson
JNJ
$618B
$45.7M 5.72%
348,653
-90,000
-21% -$12.8M
BMY icon
5
Bristol-Myers Squibb
BMY
$133B
$43.5M 5.44%
780,000
-135,000
-15% -$8.25M
SNY icon
6
Sanofi
SNY
$103B
$42.4M 5.3%
970,000
-170,000
-15% -$8.13M
XBI icon
7
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.95B
$38.7M 4.84%
500,000
-2,300,000
-82% -$204M
NVO
8
Novo Nordisk
NVO
$208B
$34.7M 4.34%
1,152,000
-128,000
-10% -$3.81M
AZN icon
9
AstraZeneca
AZN
$263B
$25.5M 3.18%
+285,000
New +$26.8M
SRPT icon
10
Sarepta Therapeutics
SRPT
$1.57B
$25.2M 3.16%
258,000
+118,000
+84% +$13.5M
ALXN
11
DELISTED
Alexion Pharmaceuticals
ALXN
$22.4M 2.8%
249,396
+133,683
+116% +$13.1M
FOLD
12
DELISTED
Amicus Therapeutics
FOLD
$18.6M 2.33%
2,017,624
-782,696
-28% -$7.44M
PFE icon
13
Pfizer
PFE
$143B
$18M 2.25%
+579,700
New +$19.8M
MSFT icon
14
Microsoft
MSFT
$3.45T
$14.8M 1.85%
93,964
+35,223
+60% +$5.79M
ABBV icon
15
AbbVie
ABBV
$443B
$12.6M 1.57%
+165,000
New +$14.1M
NVS icon
16
Novartis
NVS
$297B
$11.5M 1.44%
140,000
-60,000
-30% -$5.35M
KPTI icon
17
Karyopharm Therapeutics
KPTI
$43.5M
$10.6M 1.32%
36,667
+14,667
+67% +$4.05M
AMZN icon
18
Amazon
AMZN
$2.92T
$10.3M 1.29%
105,400
+31,400
+42% +$3.04M
QURE icon
19
uniQure
QURE
$3.03B
$9.54M 1.19%
201,107
+61,593
+44% +$3.54M
CNCE
20
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$8.96M 1.12%
1,013,039
+873,039
+624% +$8.61M
XFOR icon
21
X4 Pharmaceuticals
XFOR
$375M
$8.73M 1.09%
29,107
+5,107
+21% +$1.45M
ALLT icon
22
Allot
ALLT
$372M
$8.65M 1.08%
915,302
-55,364
-6% -$553K
YMAB
23
DELISTED
Y-mAbs Therapeutics
YMAB
$8.02M 1%
307,379
+94,086
+44% +$2.73M
XLP icon
24
State Street Consumer Staples Select Sector SPDR ETF
XLP
$14.2B
$7.91M 0.99%
+145,207
New +$8.81M
ZYME icon
25
Zymeworks
ZYME
$1.61B
$7.34M 0.92%
206,830
+49,830
+32% +$2.04M
1
2 3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q1 2020 Portfolio in Review

As of Q1 2020, Sphera Funds Management held 111 positions worth $800M, down 34% from $1.21B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Sphera Funds Management withdrew a net $240M in Q1 2020, closing 33 positions and reducing 27 holdings. Its most notable exit was BioMarin Pharmaceuticals, an estimated $21.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 66% of assets, up from 52% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Sphera Funds Management opened a new position in AstraZeneca worth $25.5M.

  • Sphera Funds Management's largest Q1 2020 buy was AstraZeneca: 285,000 shares worth $25.5M.
  • Sphera Funds Management added most to Merck in Q1 2020, an estimated $25.8M increase.
  • Sphera Funds Management's biggest Q1 2020 reduction was Johnson & Johnson, cutting an estimated $12.8M.
  • Sphera Funds Management fully exited BioMarin Pharmaceuticals in Q1 2020, selling an estimated $21.3M.
  • Sphera Funds Management's ten largest holdings make up 60% of its $800M portfolio in Q1 2020.
  • Sphera Funds Management opened 25 new positions and closed 33 in Q1 2020.
  • Sphera Funds Management's portfolio value fell 34% quarter-over-quarter to $800M.

Based on Sphera Funds Management's 13F filing for Q1 2020, filed 14 May 2020.